Aerovate Therapeutics Finalizes Merger with Jade Biosciences Following Stockholder Approval Aerovate Therapeutics and Jade Biosciences are set to merge after stockholder approval. This deal promises a new era for both biotech firms with strategic growth plans.

Aerovate Therapeutics Finalizes Merger with Jade Biosciences Following Stockholder Approval #United_States #Waltham #Merger #Aerovate #Jade_Biosciences

Aerovate Therapeutics Announces Special Cash Dividend Amid Merger with Jade Biosciences Aerovate Therapeutics has declared a significant cash dividend of $69.6 million in anticipation of its merger with Jade Biosciences, hitting stakeholders' eyes.

Aerovate Therapeutics Announces Special Cash Dividend Amid Merger with Jade Biosciences #United_States #Waltham #Cash_Dividend #Aerovate_Therapeutics #Jade_Biosciences

Aerovate Therapeutics Plans Significant Cash Dividend for Shareholders Post-Merger with Jade Biosciences Aerovate Therapeutics is preparing to announce an expected cash dividend of $67.6 to $69.6 million for its shareholders in connection with its merger with Jade Biosciences.

Aerovate Therapeutics Plans Significant Cash Dividend for Shareholders Post-Merger with Jade Biosciences #United_States #Waltham #Aerovate_Therapeutics #merger_news #Jade_Biosciences